Phase I/II Study of SCTB39G in Advanced Solid Tumours

An Open Multi-center Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of SCTB39G in Adult Patients With Advanced Malignant Solid Tumours

This study aims to evaluate the safety, tolerability, PK characteristics, immunogenicity, and preliminary anti-tumor efficacy of SCTB39G as a monotherapy in adult patients with advanced malignant solid tumours. This study is an open label, multicentre, dose-escalation and dose-expansion Phase I/II clinical trial.

Inclusion Criteria:

• 1.Voluntarily sign the informed consent form (ICF);
• 2.Male or female, ≥ 18 years and ≤ 70 years old;
• 3.Survival duration more than 3 months;
• 4.ECOG score ≤ 1 point;
• 5.histologically or cytologically confirmed diagnosis of advanced malignant solid tumour；
• 6.At least one measurable tumor lession according to RECIST v1.1;
• 7.Adequate organ and bone marrow function.

Exclusion Criteria:

• 1.Has participated in another clinical study within 4 weeks prior to the first dose;
• 2.Other malignancies diagnosed within 1 years prior to the enrollment;
• 3. Participants with brainstem, meningeal, spinal metastases, or compression; active central nervous system metastases;
• 4.NSCLC at high risk of bleeding; Obvious invasion of tumor into adjacent organs of esophageal lesions leads to high risk of bleeding or fistula,or participants after endotracheal stent implantation;
• 5.Participants with portal hypertension due to portal vein tumor thrombus at risk of bleeding;
• 6.Presence of pleural effusion, peritoneal effusion, or ascites;
• 7.Received chemotherapy, immunotherapy, biologic therapy, or other antitumor treatments within 4 weeks before enrollment
• 8.History of permanent discontinuation of immunotherapy due to immune-related toxicity or occurrence of ≥ Grade 3 irAEs;
• 9.Presence of any active autoimmune disease or a history of autoimmune disease with an expected recurrence;
• 10.History of severe allergies, severe drug allergies (including unapproved investigational drugs);
• 11.History of organ transplantation or stem cell transplantation;
• 12.Need for immunosuppressive drugs within 2 weeks prior to enrollment or anticipated during the study;
• 13.Pregnant or breastfeeding female.